Skip to content Skip to sidebar Skip to footer

Факти за ракот на грлото на матката, Гардасил и студии

11/12/2023

Ставот на јавното здравство, поддржан силно од медиумите,  е дека „вакцините се безбедни и ефикасни“, а несаканите реакции се „еден во милион“.  Една од најконтроверзната вакцина наметната за млади тинејџери е Гардасил 9, која беше вметната и во Законот за заштита на населението од заразни болести и за која се тврдеше дека превенира  добивање на рак на грлото на матката, за да сега  „го намалува ризикот од настанување на рак на грлото на матката“. Иако беше наметната како „спас“ од ракот, пред да донесете одлука за оваа медицинска интервенција, потребно е да бидете информирани за предностите, но и несаканите ефекти од ХПВ вакцината, како и факти кои се однесуваат на ракот на грлото на матката.

 

Факти што треба да ги знаете за ракот на грлото на матката

 

  1. Според Националното здружение за рак, стапките на смртност од рак на грлото на матката се намалиле за 75% откако ПАП тестот беше широко имплементиран пред повеќе од 50 години.
  2. Има помалку од 1% доживотен ризик за развој на рак на грлото на матката и помалку од една четвртина од 1% животен ризик од смрт од рак на грлото на матката. Тоа значи дека 3 на 100.000 жени умираат од рак на грлото на матката во САД годишно.
  3. Постојат десетици ХПВ поврзани со рак на грлото на матката. Сепак, кај 90% од жените, ХПВ се расчистуваат сами во рок од две години. Од преостанатите 10% ХПВ инфекции, само половина ќе се развијат во рак на грлото на матката. Само кога ХПВ вирусот опстојува многу години, абнормалните клетки може да се претворат во рак.
  4. Должината на времето потребно за развој на инвазивен карцином на грлото на матката по идентификацијата на прекурсорните лезии е во просек помеѓу 8,1 и 12,6 години и може да трае до 40 години.
  5. Скоро сите смртни случаи од рак на грлото на матката може да се спречат со едноставен ПАП скрининг и соодветно следење.

 

 

Факти што треба да ги знаете за Гардасил 9

 

  1. Целта на вакцината е да го поттикне телото да создаде антитела за седум ХПВ вируси поврзани со рак на грлото на матката и два ХПВ вируси кои предизвикуваат генитални брадавици.
  2. Вакцината наводно е ефикасна во поттикнувањето на саканите антитела, но не е познато колку долго трае оваа заштита. Се чини дека трае пет години, по што можеби ќе треба засилувач и, се разбира, не се справува со сите ХПВ вируси поврзани со рак на грлото на матката.
  3. Гардасил и Гардасил 9 никогаш не се покажало дека всушност го спречуваат ракот на грлото на матката или кој било друг рак. Затоа, неопходно е да се продолжи со редовни ПАП-скрининг  тестови за рак на грлото на матката.
  4. Овие вакцини за ХПВ не го лекуваат ракот на грлото на матката. Со децении нема да се знае дали вакцината има некаков ефект врз спречувањето на ракот на грлото на матката.
  5. Жените со претходна или активна изложеност на целните ХПВ во моментот на инокулација имаат значително зголемен ризик (44,6%) за развој на тешка дисплазија или рак на грлото на матката доколку се вакцинирани. Не постои претходно тестирање за да се види дали некој е изложен на таков ризик.
  6. Гардасил содржи алуминиумов адјуванс кој е познат невротоксин. Концентрацијата на алуминиум во Гардасил е 18.000 пати поголема од она што АХЛ го смета за безбедно во производите за инјектирање. Гардасил 9 содржи двојно поголема количина на алуминиум од Гардасил. (§201.323 Алуминиум во големи и мали количества парентерали што се користат во целосна парентерална исхрана. Федерален регистар/Правила и регулативи. Том 68 (106) вторник, 3 јуни 2003 година. Страна 32981)
  7. Гардасил/Гардасил 9 е поврзан со најмалку исто толку сериозни несакани дејства колку што има смртни случаи од рак на грлото на матката што се развиваат годишно. Неодамнешните истражувања покажаа зголемување на ракот на грлото на матката кај вакцинираната популација. Сериозните настани вклучуваат згрутчување на крвта, воспаление на органи, белодробна емболија, напади, респираторни, торакални и медијастинални нарушувања, моторни нарушувања, парализа, исцрпувачки главоболки, вртоглавица, екстремен замор, срцева аритмија, Гилијане Баре, енцефалитис и смрт. DHHS (Оддел за здравство и човечки услуги на САД)  призна дека Гардасил предизвикал смрт.
  8. Вакцината беше брзо процесуирана од FDA и беше одобрена за само шест месеци. Бидејќи се следеше брзо, нема долгорочни безбедносни студии, нема студии за интеракцијата со други вакцини дадени истовремено и нема студии за интеракцијата со апчиња за контрацепција.
  9. Ефектот врз фетусот или репродукцијата е непознат. Поголем број доенчиња чии мајки примале Гардасил имале акутни респираторни заболувања во споредба со доенчиња чии мајки примале плацебо.
  10. Вакцината не е евалуирана за потенцијалот да предизвика канцерогеност или генотоксичност.

 

Гардасил е поврзан со најмалку исто толку сериозни несакани настани колку што има смртни случаи од рак на грлото на матката што се развиваат секоја година.

Единствената позната придобивка од примањето три дози Гардасил ќе биде поголема шанса нивните ПАП тестови во следните 5 години да бидат нормални.

Родителите и жените мора да знаат дека смртните случаи се случуваат.

Горенаведените цитати се од д-р Дајан Харпер, поранешен главен истражувач за клиничките испитувања на Гардасил за Мерк. Прочитајте повеќе овде.

И покрај вакцината против ХПВ, стапката на рак на грлото на матката постојано расте

 

Линкови до студии за ХПВ вакцината

 

Овие се само мал дел од студиите во врска со ХПВ вакцините. Повеќе студии можете да најдете на страната на www.sanevax.org ,  www.nvic.org . Покрај големиот број на студии, постојат и голем број на сведоштва, документарни филмови, но и судски процеси за штета предизвикана од ХПВ вакцините за кои доста долго ги чуваме под тепих и време е да излезат од превезот на корумпираната политика.

 

 

Трудови за смртни случаи по инокулации со Гардасил:

 

  1. Dong Y. Undeniable Death Cases After HPV Vaccination. The HPV Vaccine: A Double-Edged Sword? (Part 1).June 25,2023.  www.theepochtimes.com/health/undeniable-death-cases-after-gardasil-vaccination_5328126.html

1.Dahan S, Segal Y, Dagan A, Shoenfeld Y, Eldar M, Kanduc D. Cardiac arrest following HPV vaccination. Open Access Text . DOI: 10.15761/CRT.1000279. https://www.oatext.com/pdf/CRT-5-279.pdf .

2.  Tomljenovic, L and Shaw CA. Death after Quadrivalent Human Papillomavirus (HPV) Vaccination: Causal or Coincidental?

Pharmaceutical Regulatory Affairs: Open Access. 2012. S12.001. http://www.rescuepost.com/files/ltshaw-death-after-quadrivalent-hpv-vaccination-pharma-reg-affairs-2012.pdf.

Истражувачите пронајдоа докази за имунореактивност на ѕидот на церебралните крвни садови со HPV-16L1, што се чини дека предизвика фатална васкулопатија во два случаи на ненадејна необјаснета смрт по вакцинацијата со Гардасил.

http://dx.doi.org/10.4172/2167-7689.S12-001.

 

Трудови за оваријална инсуфициенција и неплодност по Гардасил:

 

3. Warning from the American College of Pediatricians regarding premature ovarian failure following Gardasil vaccination: https://www.acpeds.org/the-college-speaks/position-statements/health-issues/new-concerns-about-the-human-papillomavirus-vaccine  January 2016.

4,  Colafrancesco S, Perricona C, et al.  Human papillomavirus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. American Journal of Reproductive Immunology 2013, 70,309,

Documented “evidence of the potential of the HPV Vaccine to trigger a life disabling autoimmune condition.” http://www.ncbi.nlm.nih.gov/pubmed/23902317

5.  Little, DT and Ward, HRG. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomarvirus vaccination, BMJ Case Reports 2012; dol:101136 /bcr-2012-006879.   http://casereports.bmj.com/content/2012/bcr-2012-006879.abstract Acessed 10/20/2012.  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543769/ Accessed 12/26/16.  A study reporting premature ovarian failure and sterility in an adolescent girl following inoculations with Gardasil.

6.   Little DT, Ward HRG. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination A Case Series Seen in General Practice. Journal of Investigative Medicine High Impact Case Reports, 2014, 2(4),      1. http://hic.sagepub.com/content/2/4/2324709614556129.full

7.   Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015 Aug;27(4):265-70. doi: 10.1097/GCO.0000000000000183. Review. http://www.ncbi.nlm.nih.gov/pubmed/26125978

8.  DeLong G. A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus vaccine injection. Journal of Toxicology and Environmental Health, Part A. Volume 81, 2018 – Issue 14. Accessed 11/29/18.  https://www.tandfonline.com/doi/abs/10.1080/15287394.2018.1477640?journalCode=uteh20

 

 

Трудови за скриените токсични состојки во вакцините за ХПВ:

 

9. Brawer AE. Hidden Toxicity of Human Papillomavirus Vaccine Ingredients. Journal of Rheumatic Diseases and Treatment. 2019, Aug. 07. 5:075. Vol. 5/issue 3. DOI:10.23937/2469-1510075 .

10. Brawer AE, Sullivan, DH. The expanding cocktail of harmful ingredients in human papillomavirus vaccines. Frontiers in Women’s Health. 2020, Nov. 10, Vol. 5: 1-4. https://www.oatext.com/the-expanding-cocktail-of-harmful-ingredients-in-human-papillomavirus-vaccines.php#gsc.tab=0

Нова студија открива дека вакцините за ХПВ предизвикуваат сериозни нарушувања на нервниот систем

 

Трудови за автоимуни нарушувања предизвикани од алуминиумов адјуванс и токсичност на ДНК во вакцините за ХПВ:

 

11.  Inbar R,Weiss R, Tomljenovic L, Arango MT, Deri Y, Shaw CA, Chapman J,Blank M, Shoenfeld Y. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.  Immunol Res. DOI

10.1007/s12026-016-8826-6. 2016 Jul 16. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27421722.  http://hpvupdate.com/wp-content/uploads/2016/06/Gardasil-20-9-2015-LT-EDITED-FINAL-VERSION-FOR-SUBMISSION.pdf . Immunohistochemistry analysis revealed microglial activation in the CA1 area of the hippocampus of Gardasil injected mice. It appears that Gardasil via its Al adjuvant and HPV antigens has the ability to trigger neuroinflammation and autoimmune reactions, further leading to behavioral changes.

12.  Lee, SH. Detection of human papillomavirus (HPV) L1gene DNA possibly bound to particulate aluminum adjuvant in the HPVvaccine Gardasil. Journal of Inorganic Biochemistry.117 (2012) 85-92. www.elsevier.com/locate/jinorgbio. Researcher discovers and documents that Gardasil contains potentially dangerous HPV DNA contaminants.

13.  Shoenfeld Y, Agmon-Levin N. ‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants. Journal of Autoimmunity (2010), 2010; XXX: 1-5.“…we suggest that these four somehow enigmatic conditions: siliconosis, MMF, GWS and post-vaccination phenomena that share clinical and pathogenic resemblances will be included under a common syndrome entitled the ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants (ASIA).’”

14.  Tomljenovic L, Shaw CA.  Mechanisms of Aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 2012; 21:223-230. “In summary, research evidence shows that increasing concerns about current vaccination practices may indeed be warranted.”

15. Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem 2009; 103: 1555-1562.

16. Anaya JM, Reyes B, Perdomo-Arciniegas AM, Camacho-Rodríguez B, Rojas-Villarraga A. Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine. Clin Exp Rheumatol, 2015, 33(4), 545 http://www.ncbi.nlm.nih.gov/pubmed/25962455

  1. Exley C. Aluminium-based adjuvants should not be used as placebos in clinical trials. Vaccine. 2011;29(50):9289. Vaccine. 2011 Nov 21;29(50):9289. doi: 10.1016/j.vaccine.2011.08.062. Epub 2011 Aug 25. http://www.sciencedirect.com/…/article/pii/S0264410X11013089

 

 

Трудови за сериозни несакани дејства по вакцинирање против ХПВ:

 

18  . Tomljenovic L, Tarsell E, Garrett J, Shaw CA & Holland MS. Significant Under-Reporting of Quadravalent Human Papillomavirus Vaccine-Associated Serious Adverse Events in the United States: Time for Change?  Science, Public Health Policy and the Law. May, 2021; Vol. 2: 37-58. Researchers found that the CDC has been failing to acknowledge as serious and record reports of citizens who had “persistent or significant disability/incapacity” following Gardasil vaccinations even though that is one of the criterion defining a serious adverse event in the Code of Federal Regulations.  Failure to count this category of  adverse events as serious appears to have hidden major safety problems with Gardasil vaccines.

19. Delépine N,  Delépine G. Gardasil. Faith and propaganda versus hard evidence. April 4, 2019. The authors evaluate the HPV vaccination results on the incidence of invasive cervical cancer in different countries.The registers analysis reveals an increase in the cancer incidence following the vaccination campaign which affects almost exclusively the most vaccinated age groups. Gardasil trials have proved its effectiveness against HPV infection, genital warts and benign dysplasia, but not against invasive cancer. http://docteur.nicoledelepine.fr/gardasil-faith-and-propaganda-versus-hard-evidence/

20, Brinth LS, Pors K, Theibel  AC, et al. Orthostatic intolerance and postural tachycardia syndrome as suspecteae Ld adverse effects of vaccination against human papilloma virus. Vaccine. 2015; 33(22): 2602-05.

http://www.sciencedirect.com/…/pii/S0264410X15004375

21. Brinth L, Theibel AC, Pors K, et al. Suspected side effects to the quadrivalent human papilloma vaccine. Danish Med J. 2015; 62(4): A5064. http://www.danmedj.dk/…/PAST_ISSUE/2015/DMJ_2015_04/A5064

22. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2010; 17 (7): 52. http://dx.doi.org/10.1111/j.1468-1331.2010.03021.x

23. Blitshetyn S, Brinth L., Hendrickson J. E., Martinez-Lavin M. Autonomic dysfunction and HPV immunization: an overview. Immunologic Research. 2018 Nov 27. Accessed on line Nov 30, 2018:   https://link.springer.com/content/pdf/10.1007%2Fs12026-018-9036-1.pdf . “There is substantial evidence from case series reported from various countries that the HPV vaccine may be associated with phenotypic syndromes that share common pathogenesis involving the autonomic nervous system, potentially including underlying autoimmune processes.”

24. Martinez-Lavin M, Amezcua-Guerra L. Serious adverse events after HPV vaccination:a critical review of randomized trials and post-marketing case series. Clin Rheumatol. 20 July 2017; DOI 10.1007/s10067-017-3768-5.  https://www.ncbi.nlm.nih.gov/pubmed/28730271

25. Martinez-Lavin M, Martinez-Martinez LA, Reyes-Loyola P. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015; 34 (11): 1981-83.doi: 10.1007/s10067-015-3070-3. Epub 2015 Sep 10  https://www.ncbi.nlm.nih.gov/pubmed/26354426

26. Martinez-Lavin M. Hypothesis: Human papillomavirus vaccination syndrome-small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol. 2015; 34 (7): 1165-69. doi:10.1007/s10067-015-2969-z. Epub 2015 May 20. Review. https://www.ncbi.nlm.nih.gov/pubmed/…

27. Martinez-Lavin M. Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination. J Clinical Rheumatol. 2014; 20 (7): 392-93.

28. Joelving F. Flaws in the clinical trial for Gardasil made it harder to properly assess safety. Slate. Dec. 17, 2017.  https://slate.com/health-and-science/2017/12/flaws-in-the-clinical-trials-for-gardasil-made-it-harder-to-properly-assess-safety.html .

29. Richards S, Chalkiadis G, Lakshman R, et al.  Complex regional pain syndrome following immunisation. Arch Dis Child. 2012; 97 (10): 913-15.

30. Spila-Alegiani S, Da Cas R, Giambi C, Raschetti R, Salmaso S. An Italian study found that 61% of women experienced an adverse event after the administration of the first dose of HPV vaccine. Recenti Prog Med. 2013 Jun; 104(6): 262-6. PMID: 23801230.

31, Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccination may contribute to causing a wide variety of autoimmune disorders. Discov Med. 2010, Feb; 9 (45): 90-7. PMID: 20193633.

32. Kinoshita T, Abe R, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine.  Internal Medicine.2014; 53 (19); 2185-200.

http://www.ncbi.nlm.nih.gov/pubmed/25274229  The symptoms observed in this study can be explained by abnormal peripheral sympathetic responses following hpv vaccination.The social problems of the study participants remained unresolved in that the severely disabled girls stopped going to school.

33. Brotherton, JML, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAL 2008; 179 (6): 525-33.“Based on the number of confirmed cases, the estimated rate of anaphylaxis following quadrivalent HPV vaccine was significantly higher than identified in comparable school-based delivery of other vaccines.”

34. Corte, CD, et al. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in an 11-year-old girl. Vaccine. 2011; 29: 4654-4656 .http://www.ncbi.nlm.nih.gov/pubmed/21596082“….we suggest that the occurrence of the autoimmune hepatitis may be related to the stimulation of immune system by adjuvated-vaccine, that could have triggered the disease in a genetically predisposed individual.”

35. Souayah N, et al. Guillain-Barre syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine. 2011; 29 (5):886-89. “Using data from Vaccine Adverse Event Reporting System, we identified 69 reports of Guillain-Barre Syndrome (GBS) after Gardasil vaccination that occurred in the U.S. between 2006 and 2009. …The estimated weekly reporting rate of post-Gardasil GBS within the first 6 weeks (6.6 per 10,000,000) was higher than post-Menactra and post-influenza vaccinations.”

36. Jesitus J. HPV vaccine possibly linked to cutaneous PAN. Dermatology Times, Aug 2009.  http://www.modernmedicine.com/modernmedicine/Dermatology/HPV-vaccine-possibly-linked-to-cutaneous-PAN/ArticleStandard/Article/detail/616459

37. Hull JHK, Mead SH, Foster OJ, Modarres-Sadeghi H. Severe vasculitic neuropathy following influenza vaccination. Journal of Neurology, Neurosurgery, and Psychiatry, 75:507-508, 2004.

38. Sutton I, Lahoria R,Tan I, Clouston P,Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Muscular Sclerosis, 00:1-4,2008. Mult Scler. 2009 Jan; 15 (1): 116-9. E pub 2008 Sep 19. PMID: 18805844. Human Papilloma Virus  (HPV) vaccine is associated with demyelinating events. Report of motor neuron disease after HPV vaccine, 2009. Available from World Wide Web: www.medscape.com/viewarticle/711461. Also, http://www.ncbi.nlm.nih.gov/pubmed/18805844 . Paper presented at the American Neurological Association (ANA) 134th Annual Meeting (link last accessed February 5, 2010).

39. Kandu D. Quantifying the possible cross-reactivity risk of an HPV 16 vaccine. Journal of Experimental Therapeutics and Oncology, 2009;Vol. 8(1): 65-76. http://www.ncbi.nlm.nih.gov/pubmed/…

40. Álvarez-Soria MJ, Hernández-González A, Carrasco-García de León S, del Real-Francia MÁ, Gallardo-Alcañiz MJ, López-Gómez JL. Demyelinating disease and vaccination of the human papillomavirus. Rev Neurol, 2011, 52, 472. http://www.ncbi.nlm.nih.gov/pubmed/21425100

41. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol-Neurosurg Psychiatry, 2010, 1-3. http://jnnp.bmj.com/…/2010/10/08/jnnp.2010.214924.extract

42. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med J Aust, 2008, 189, 178. http://www.ncbi.nlm.nih.gov/pubmed/18673112

43. DiMari J Jr, Hajjar M, Ciesielski T. A 16-Year-Old Girl With Bilateral Visual Loss and Left Hemiparesis Following an Immunization Against Human Papilloma Virus. J Child Neurol, 2010, 25, 321. http://www.ncbi.nlm.nih.gov/pubmed/20189933

44. Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y. Human papillomavirus vaccine and systemic lupus erythematosus, Clinical Rheumatology, 2013, 32, 1301. http://www.ncbi.nlm.nih.gov/pubmed/23624585

45. Melo Gomes S, Glover M, Malone M, Brogan P. Vasculitis following HPV immunization. Rheumatology, 2013, 52, 581. http://rheumatology.oxfordjournals.org/content/52/3/581.long

46. Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfi el ML, Muniz Montes JR. Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia, 2010, 25,      58. http://www.ncbi.nlm.nih.gov/pubmed/20388462

47. Marco Rossia, Chiara Bettini, Caterina Paganoc. Bilateral Papilledema Following Human Papillomavirus Vaccination. J Med Cases, 2011, 2, 222. http://www.journalmc.org/index.php/JMC/article/view/256

48. Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G. Immune thrombocytopenic purpura following human papillomavirus vaccination.Vaccine, 2009, 27, 3690. http://www.ncbi.nlm.nih.gov/pubmed/19464550

49. Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring HP., Aichner FT. HPV vaccine: a cornerstone of female health a possible cause of ADEM. J Neurol 2008, 255, 1818. http://link.springer.com/…/10.1007%2Fs00415-008-0867-x

50. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus.. Neurology, 2009, 72, 2132. http://www.neurology.org/content/72/24/2132.extract

51. Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants”: Case Report and Literature Review. Journal of Investigative Medicine High Impact Case Reports, 2014, 2(1), 1. http://hic.sagepub.com/content/2/1/2324709614527812.full

52. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. European Journal of Neurology, 2014, 21, 135 http://www.ncbi.nlm.nih.gov/pubmed/24102827

53. Yonee C, Toyoshima M, Maegaki Y, Kodama Y, Hayami H, Takahashi Y, Kusunoki S, Uchibori A, Chiba A, Kawano Y. Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report. Neuropediatrics, 2013, 44(5), 265. http://www.ncbi.nlm.nih.gov/pubmed/23378179

54. Wehbe E. A catastrophic failure. http://dx.doi.org/10.1016/j.amjmed.2010.09.020

55. Palmieri B, Poddighe D, Vadalà M, Laurino C, Carnovale C, Clementi E. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res (2016). http://link.springer.com/article/10.1007/s12026-016-8820-z

56. Bizjak M ,Bruck O , Kanduc D, Praprotnik S, Shoenfeld Y. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Seminars in Hematology. Volume 53, Supplement 1, 2016, S48–S50 http://www.sciencedirect.com/…/pii/S0037196316300269

57. Bizjak M, Bruck O, Praprotnik S, Dahan S, Shoenfeld Y. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunol Res. 2016. http://link.springer.com/article/10.1007%2Fs12026-016-8823-9

58. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Medical Journal of Australia. 189, 3, 2008 https://www.mja.com.au/…/189_03…/letters_040808_fm.pd

59. Kafaie J, Kim M, Krause E. Small Fiber Neuropathy Following Vaccination. J Clin Neuromuscul Dis. 2016 Sep;18(1):37-40. doi: 10.1097/CND.0000000000000130. https://www.ncbi.nlm.nih.gov/pubmed/27552388

60. Blitshteyn S, Brook J. Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination.. Immunol Res. 2016 Aug 25 https://www.ncbi.nlm.nih.gov/pubmed/27561785

61. Hotta O, Tanaka A, Torigoe A, Imai K, Ieiri N. Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA). Japanese Focal Inflammation Research Group. Immunol Res. 2016 Sep 3. https://www.ncbi.nlm.nih.gov/pubmed/27592233

62. Yonee C, Toyoshima M, Maegaki Y, Kodama Y, Hayami H, Takahashi Y, Kusunoki S, Uchibori A, Chiba A, Kawano Y. Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report. Neuropediatrics. 2013 Oct;44(5):265-7. doi: 10.1055/s-0033-1333873. Epub 2013 Feb 1. http://www.ncbi.nlm.nih.gov/pubmed/23378179

63. Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A. Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination. Pharmacotherapy. 2008 Sep;28(9):1194-7. doi: 10.1592/phco.28.9.1194. http://www.ncbi.nlm.nih.gov/pubmed/?term=18752390

64. Pérez-Carmona L, Aguayo-Leiva I, González-García C, Jaén-Olasolo P. The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration | 2010. Dermatology. 2010;221(3):197-200. doi: 10.1159/000319852 http://www.karger.com/Article/Abstract/319852

65. Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? | 2012, Lupus. 2012 Feb;21(2):158-61. doi: 10.1177/0961203311429556. http://www.ncbi.nlm.nih.gov/pubmed/?term=22235047Free

66. Wise LD, Wolf JJ, Kaplanski CV, Pauley CJ, Ledwith BJ. Lack of effects on fertility and developemental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects. 1) long-term ovarian function was not assessed in either the original rat safety studies3,4 or in the human vaccine trials, New concerns about the human Papillomavirus Vaccine from American College of Pediatricians https://www.acpeds.org/…/new-concerns-about-the-human-papil…

67. Segal L, Wilby OK, Willoughby CR, Veenstra S, Deschamps M. Evaluation of the intramuscular administration of CervarixTM vaccine on fertility, pre- and post-natal development in rats. 1) long-term ovarian function was not assessed in either the original rat safety studies3,4 or in the human vaccine trials, New concerns about the human Papillomavirus Vaccine from American College of Pediatricians https://www.acpeds.org/…/new-concerns-about-the-human-papil…

  1. Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxinhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105142/

 

25 причини да се одбие вакцината Гардасил

 

 

 

Трудови и сведоштва во врска со замена на вирусот на ХПВ, можен зголемен ризик од ХПВ по инокулации и ко-фактори за ризик од рак на грлото на матката:

 

69. Hildesheim A, Herrero R, Wacholder S, Rodriguez A C, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR. HPV vaccine does not have a therapeutic effect in young women with pre-existing human papillomavirus infection. JAMA. 2007 Aug 15; 298 (7): 743-53. PMID:17699008

69. Spinosa JP. Letter to the Editor. Cancer Letters 2011; 304:70. In a recent letter to the Editor by Dr. Jean Pierre Spinosa which was published in Cancer Letters, Dr. Spinosa discusses the possibility of viral replacement of the targeted HPVs by other high risk HPVs associated with cervical cancer. In addition, there is evidence that for women with positive HPV 16 or 18 at the time of vaccination, there is an increased risk of CIN 2/3 precancerous lesions or cervical cancer itself.

70. Lee, NC., Associate Director for Science, CDC.  Testimony on cervical cancer before the House Committee, Subcommittee on Health and Environment. March 16, 1999. While the high risk hpvs are necessary, they are not sufficient to cause cervical cancer. According to testimony on cervical cancer given by Dr. Nancy C. Lee before a Congressional Committee, cofactors like sexual behaviors, smoking, and immunosuppressive disorders play a role. She also states,” the most important risk factor for developing cervical cancer… is the failure to receive regular screening with a Pap smear.”

71. VRBPAC Meeting. VRBPAC Background Document. Gardasil HPV Quadrivalent Vaccine. May 18, 2006; 13-14. wayback.archive-it.org/7993/20170405062303/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf Originally accessed February 20, 2012. Reaccessed 5/31/2022. VRBPAC meeting at which it was disclosed that woman who already had the targeted 16 or 18 HPVs  had a 44.6% increased risk of developing precancerous lesions or cervical cancer if they received the vaccine. 

  1. Wright TC Jr, Stoler MH, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206: 46.el-46.ell. (see Table 3). Table 3 of this study compared hpvs present in HPV vaccinated and unvaccinated women. The study showed a drop of a mere 0.6% of HPV 16 and 1.1% decrease in HPV 18. At the same time, however, the vaccinated women had a 4 to 10x increase in all of the other high risk, potentially cancerous HPVs.

 

Документарен филм: „Под кожата“ – Механизми на повреда од ХПВ вакцините

 

 

 

Други трудови во врска со ХПВ и рак

 

73.  Balanda M, Quiero A, Vergara N, Espinoza G, Martín HS, Rojas G, Ramírez E. Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015. Med Microbiol Immunol. 2016 Aug 18. [Epub ahead of print] This Chilean study found less than 60% of women with “abnormal cytology” to have hpv infection. HPV may not be causing the cancer. Considering the emerging evidence that those who have cancer and are hpv positive have better survival times than those with similar cancers yet no hpv, we must reconsider the role of hpv in the cancer. https://www.ncbi.nlm.nih.gov/pubmed/27539577

74. Svahn MF, Munk C, Nielsen TS, von Buchwald C, Frederiksen K, Kjaer SK. Trends in all-cause five-year mortality after head and neck cancers diagnosed over a period of 33 years. Focus on estimated degree of association with human papillomavirus. Acta Oncol. 2016 Aug 23:1-7 Further evidence of the positive role of HPV infection in cancer survival rates. https://www.ncbi.nlm.nih.gov/pubmed/27550781

75. Neil Ari Wijetunga NA, Ben-Dayan M, Tozour J, Burk RD, Schlecht NF, Einstein MH, Greally JM. A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma Epigenetic causes often associated with environmental triggers, we need to take a closer look at the causes of hpv related cancer. http://www.impactjournals.com/oncotarget/index.php…

76. Rivera-Peña B, Ruíz-Fullana FJ, Vélez-Reyes GL,Rodriguez-Benitez RJ, Marcos-Martínez MJ, Trinidad-Pinedo J, Báez A.HPV-16 infection modifies overall survival of Puerto Rican HNSCC patients Infect Agent Cancer. 2016; 11(1): 47. Published online 2016 Aug 24 HPV infected cancer patients lived on average two thirds longer than non hpv infected patients with the same types of cancer. It seems these cancers are associated with smoking and drinking, and the presence of hpv 16 keeps them alive on average three and a half years longer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995614/

77. Burger EA, Lee K, Saraiya M, Thompson TD, Chesson HW, Markowitz LE, Kim JJ. Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. Cancer. 2016 Jul 1;122(13):2057-66. doi: 10.1002/cncr.30007. Epub 2016 Apr 28. http://www.ncbi.nlm.nih.gov/pubmed/27124396

78. Mahmud SM. HPV vaccine may not protect women against high-grade squamous intraepithelial lesions, dysplasias J Clin Oncol. 2014;doi:10.1200/JCO.2013.51.4265. http://www.healio.com/…/hpv-vaccine-may-not-protect-women-a…

79. Bui TC, Thai TN, Tran LT, Shete SS, Ramondetta LM, Basen-Engquist KM. Association between Vaginal Douching and Genital Human Papillomavirus Infection among Women in the United States. J Infect Dis. 2016 Aug 23. pii: jiw388 http://m.jid.oxfordjournals.org/…/22/infdis.jiw388.abstract…

80. Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N,Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. Retrospective International Survey and HPV Time Trends Study Group. http://www.ncbi.nlm.nih.gov/pubmed/25043390

81. Fischer S, Bettstetter M, Becher A, Lessel M, Bank C, Krams M, Becker I, Hartmann A, Jagla W, Gaumann A. Shift in prevalence of HPV types in cervical cytologyspecimens in the era of HPV vaccination. Oncol Lett. 2016 Jul;12(1):601-610. Epub 2016 Jun 1 https://www.spandidos-publications.com/ol/12/1/601  (free PMC, MVR-HPV)

82. Tomljenovic L, Shaw CA . No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil. J Intern Med. 2012;272(5):514–5. doi:10.1111/j.1365-2796.2012.02551.x. CrossRef PubMed http://www.ncbi.nlm.nih.gov/pubmed/…

83. Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19(8):1466-87. Review. PMID: 23016780  http://www.ncbi.nlm.nih.gov/pubmed/…

84. Verhoeven V, Renard N, Makar A, Van Royen P, Bogers JP, Lardon F, Peeters M, Baay M. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. Eur J Cancer Prev. 2013 Jan;22(1):46-51. doi: 10.1097/CEJ.0b013e328355ed23. http://www.ncbi.nlm.nih.gov/pubmed/…

85. Kennedy EM, Kornepati AVR, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells using a bacterial CRISPR/Cas RNA-guided endonuclease. Journal of Virology, August 6, 2014. DOI: 10.1128/JVI.01879-14 Free Article http://www.ncbi.nlm.nih.gov/pubmed/25100830

86. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP, Das BC. Elimination of high-risk human papillomavirus typ HPV16 infection by ‘praneem’ plyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol. 2009 Dec;135(12):1701-9. doi: 10.1007/s00432-009-0617-1. Epub 2009 Jun 13. Praneem is a purified herbal cream which includes the herb Azadirachta indica (neem tree)  http://www.ncbi.nlm.nih.gov/pubmed/…

87. Basu P, Dutta S, Begum R, Mittal S, Dutta PD, Bharti AC, Panda CK, Biswas J, Dey B, Talwar GP, Das BC. Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. Asian Pac J Cancer Prev. 2013;14(10):5753-9. PMID: 24289574 (Free Article, MVR-HPV) http://www.ncbi.nlm.nih.gov/pubmed/

  1. Andersson L. Increased incidence of cervical cancer in Sweden:Possible link with HPV vaccination.Indian Journal of Medical Ethics online. 2018 April 30: 1-4. http://ijme.in/wp-content/uploads/2018/04/20180430_increased_incidence.pdf . Accessed 5/04/18.

 

 

Трудови за етички грижи и конфликт на интереси во врска со одобрувањето на вакцината против ХПВ:

 

89.  Rees CP, Brhlikova P, Pollock A M. Will HPV vaccination prevent cervical cancer? Journal of Royal Society of Medicine; 0 (0) 1-15. DOI 10.1177/0141076819899308. 2020 https://journals.sagepub.com/doi/pdf/10.1177/0141076819899308 accessed 2/6/2020.   The trials may have overestimated the efficacy of the vaccine as some of the lesions would have regressed spontaneously. Many trials diagnosed persistent infection on the basis of frequent testing at short intervals, i.e. less than six months. There is uncertainty as to whether detected infections would clear or persist and lead to cervical changes.

90. Tomljenovic L, Shaw CA. Too Fast or Not Too Fast: The FDA’s Approval of Merck’s HPV Vaccine Gardasil. Conflicts of Interest in the Practice of Medicine. Fall 2010; 673-68 http://www.ncbi.nlm.nih.gov/pubmed/23061593  Documents how the FDA fast-track approved Gardasil despite the fact that “Gardasil failed (and continues to fail) to met a single one of the four criteria required by the FDA for Fast Track approval. Gardasil is demonstrably neither safer nor more effective than Pap screening combined with LEEP, not can it improve the diagnosis of serious cervical cancer outcomes” .

91. Sarojini NB, et al. The HPV Vaccine: Science, Ethics and Regulation. Economic and Political Weekly November 27, 2010; XLV (48): 27-34. “A recent civil society-led investigation has highlighted serious ethical violations in a trial of the Human Papilloma Virus vaccine on girls in Khammam district in Andhra Pradesh. …they illustrate how the promotional practices of drug companies, pressure from powerful international organizations, and the co-option of, and uncritical endorsement by, India’s medical associations are influencing the country’s public health priorities.” 

92. Beppu H, Minaguchi M, Uchide K, Kumamoto K, Sekiguchi M, Yaju Y. Lessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective.Indian Journal of Medical Ethics. 2017. Online ISSN: 0975-5691/ Print ISSN: 0974-8466. Paper on breaches of medical ethics re hpv vaccines.http://www.ijme.in/wp-content/uploads/2017/04/252the82_lessons_learnt.pdf .

http://ijme.in/articles/lessons-learnt-in-japan-from-adverse-reactions-to-the-hpv-vaccine-a-medical-ethics-perspective/?galley=html

93. Sarojini N, Deepa V. Trials and tribulations: an expose of the HPV vaccine trials by the 72nd Parliamentary Standing Committee Report. Indian Journal of Medical Ethics. October-December 2013;  Vol X (4): 220-222.

 

Прочитајте повеќе:

Вистината за ХПВ вакцините – Дел 1: Колку е навистина безбедна?

Вистината за ХПВ вакцините – Дел 2: Загриженост за зголемени невролошки и автоимуни настани по ХПВ вакцините

Вистината за ХПВ вакцините – Дел 3: Дали може да го спречи ракот на грлото на матката?

 

Вистината за ХПВ вакцините – Дел 4: Опасните состојки во ХПВ вакцините го зголемуваат ризикот за младите луѓе

 

Доколку сте одлучиле да не го вакцинирате Вашето дете, а добивате Покана за вакцинација од диспанзер следете ги следниве чекори:

Прашање: Добив покана за ХПВ вакцинација од диспанзер, како да постапам?